Dr Martens /£DOCS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Dr Martens
Dr. Martens, also known as Docs or DMs, is a United Kingdom-based company renowned for its iconic range of footwear, alongside a variety of clothing and accessories. The company, headquartered in Wollaston, Northamptonshire, operates primarily in the footwear manufacturing sector. Established in 1947, Dr. Martens has grown to become a symbol of self-expression and counterculture, distributing its products worldwide under the Dr. Martens brand.
- Ticker
- £DOCS
- Sector
- Consumer Discretionary
- Primary listing
- LSE
- Employees
- 2,377
- Headquarters
- London, United Kingdom
- Website
- www.drmartensplc.com
Dr Martens Metrics
BasicAdvanced
£628M
27.29
£0.02
0.24
£0.03
3.89%
Price and volume
Market cap
£628M
Beta
0.24
52-week high
£0.96
52-week low
£0.59
Average daily volume
842K
Dividend rate
£0.03
Financial strength
Current ratio
2.609
Quick ratio
1.559
Long term debt to equity
0.961
Total debt to equity
1.089
Dividend payout ratio (TTM)
103.36%
Interest coverage (TTM)
2.61%
Profitability
EBITDA (TTM)
85.7
Gross margin (TTM)
66.15%
Net profit margin (TTM)
3.11%
Operating margin (TTM)
9.47%
Effective tax rate (TTM)
27.22%
Revenue per employee (TTM)
£320,000
Management effectiveness
Return on assets (TTM)
5.12%
Return on equity (TTM)
6.54%
Valuation
Price to earnings (TTM)
27.292
Price to revenue (TTM)
0.826
Price to book
1.74
Price to tangible book (TTM)
6.89
Price to free cash flow (TTM)
4.831
Free cash flow yield (TTM)
20.70%
Free cash flow per share (TTM)
0.136
Dividend yield (TTM)
3.89%
Growth
Revenue change (TTM)
-2.88%
Earnings per share change (TTM)
413.26%
3-year revenue growth (CAGR)
-8.56%
10-year revenue growth (CAGR)
12.65%
3-year earnings per share growth (CAGR)
-42.89%
10-year earnings per share growth (CAGR)
7.18%
3-year dividend per share growth (CAGR)
-24.13%
What the Analysts think about Dr Martens
Analyst ratings (Buy, Hold, Sell) for Dr Martens stock.
Analyst projections of the future price of Dr Martens stock.
Bulls say / Bears say
Adjusted pre-tax profit rose 61% to £55 million in FY26, and management expects further strong growth in FY27. This suggests its reduced discounting and tighter cost control are improving earnings even before sales growth returns. (Reuters)
The US, its largest market, was still growing in July, with wholesale demand described as particularly encouraging; Japan and South Korea were also performing well. That offers signs of demand beyond the profit gains from cost control. (Reuters)
Product sales are showing some breadth beyond the classic boot: shoe revenue rose 19% in FY26, while newer lines Lowell, Buzz and Zebzag grew to 9% of pairs sold. If those products continue to attract buyers, they could broaden the brand’s growth drivers. (Investegate)
Revenue fell 1.4% at constant currency in FY26, while direct-to-consumer revenue was down 4.2%. The earnings recovery has therefore not yet translated into a broad sales recovery. (Investegate)
Europe remains a weak spot: revenue in EMEA declined, with the company citing a challenging consumer backdrop. Continued softness in the region could make it harder to restore full-price sales and group growth. (Reuters)
The company has already recognised previously incurred US tariff costs and is seeking refunds, leaving some uncertainty over cash recovery. Any delay in those refunds would be an additional strain while the business is still rebuilding sales. (Reuters, Investegate)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
Dr Martens Financial Performance
Revenues and expenses
Dr Martens Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Dr Martens
AllGBPUSDEUR
Fund name | Fund size | £DOCS weighting |
|---|---|---|
Vanguard FTSE 250£VMIG | £569M | 0.13% |
Vanguard FTSE 250£VMID | £1.5B | 0.13% |
iShares FTSE 250£MIDD | £672M | 0.12% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.03% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.03% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.